Ardelyx Inc. buy BiotechBee
Start price
17.02.24
/
80%
€8.30
Target price
31.01.26
€11.00
Performance (%)
-2.67%
Price
03.05.24
€8.08
Summary
This prediction is currently active. With a performance of -2.67%, the BUY prediction by BiotechBee is trending in the wrong direction. This prediction currently runs until 31.01.26. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 80% into this predictionArdelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Ardelyx Inc. | 34.723% | 34.723% |
| iShares Core DAX® | -0.922% | -1.078% |
| iShares Nasdaq 100 | 0.371% | -0.556% |
| iShares Nikkei 225® | 2.224% | -2.825% |
| iShares S&P 500 | -0.026% | -0.788% |
According to BiotechBee what are the pros and cons of Ardelyx Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread Ardelyx Inc. diskutieren
Stopped prediction by BiotechBee for Ardelyx Inc.
Ardelyx Inc.
Start price
Target price
Perf. (%)
€1.29
08.09.22
08.09.22
€2.00
31.12.24
31.12.24
31.25%
09.12.22
09.12.22
Could be very worthwhile Investment >20% year
